BCL6 and prostate carcinoma: As previously reported, up-regulated hsa-mir-127-3p in breast-cancer-negative tumours has been involved in inhibiting growth, enhanced apoptosis and migration in breast cancer cells by targeting BCL-6 oncogene [34], whilst hsa-miR-654-3p (logFC 0.07) regulates proliferation, apoptosis, migration and invasion in prostate cancer [35].